Apixaban hits the buffers in Phase III
This article was originally published in Scrip
Executive Summary
Pfizerand Bristol-Myers Squibb's investigational Factor Xa inhibitor apixaban has missed the primary endpoint in the Phase III ADVANCE-1 study for the prevention of venous thromboembolism in patients undergoing total knee replacement surgery, an early analysis of the data indicates.